Ilunocitinib: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 05:51, 21 December 2024 editWhywhenwhohow (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,061 edits add legal, names← Previous edit		Latest revision as of 06:54, 21 December 2024 edit undoBoghog (talk \| contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,621 edits added chemical categories
(2 intermediate revisions by the same user not shown)
Line 4:		Line 4:
	{{cs1 config \|name-list-style=vanc \|display-authors=6}}		{{cs1 config \|name-list-style=vanc \|display-authors=6}}
	{{Infobox drug		{{Infobox drug
	\| image =		\| image = Ilunocitinib.svg
	\| width =		\| width =
	\| alt =		\| alt =
Line 39:		Line 39:
	\| legal_UK_comment =		\| legal_UK_comment =
	\| legal_US = Rx-only		\| legal_US = Rx-only
	\| legal_US_comment = <ref name="FDA Zenrelia">{{cite web \| title=Zenrelia \| website=U.S. ] (FDA) \| url=https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141-585 \| access-date=21 December 2024}}</ref><ref name="Zenrelia FOI summary">https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15865</ref>		\| legal_US_comment = <ref name="FDA Zenrelia">{{cite web \| title=Zenrelia \| website=U.S. ] (FDA) \| url=https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141-585 \| access-date=21 December 2024}}</ref><ref name="Zenrelia FOI summary">{{cite web \| id = NADA 141-585 \| title = Zenrelia (ilunocitinib tablets) Dogs\| url = https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15865 \| publisher = U.S. ] (FDA) }}</ref>
	\| legal_EU =		\| legal_EU =
	\| legal_EU_comment =		\| legal_EU_comment =
Line 60:		Line 60:
	\| CAS_supplemental =		\| CAS_supplemental =
	\| PubChem = 44231134		\| PubChem = 44231134
	\| IUPHAR_ligand =		\| IUPHAR_ligand = 11670
	\| DrugBank =		\| DrugBank =
	\| ChemSpiderID =		\| ChemSpiderID = 115006748
	\| UNII = N3TB5AH8B9		\| UNII = N3TB5AH8B9
	\| KEGG =		\| KEGG =
	\| ChEBI =		\| ChEBI =
	\| ChEMBL =		\| ChEMBL = 4802241
	\| NIAID_ChemDB =		\| NIAID_ChemDB =
	\| PDB_ligand =		\| PDB_ligand =
Line 74:		Line 74:
	\| IUPAC_name =		\| IUPAC_name =
	\| C = 17 \| H = 17 \| N = 7 \| O = 2 \| S = 1		\| C = 17 \| H = 17 \| N = 7 \| O = 2 \| S = 1
	\| SMILES =		\| SMILES = C1CC1S(=O)(=O)N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4
			\| StdInChI = InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)
	\| StdInChI =
	\| StdInChI_comment =		\| StdInChI_comment =
	\| StdInChIKey = RVOUEXFKIYNODQ-UHFFFAOYSA-N		\| StdInChIKey = RVOUEXFKIYNODQ-UHFFFAOYSA-N
Line 90:		Line 90:
	}}		}}

	'''Ilunocitinib''', sold under the brand name '''Zenrelia''', is a ] used for the treatment of ] (itching) in dogs.<ref name="CA PDL additions" /><ref name="Zenrelia FOI summary" />		'''Ilunocitinib''', sold under the brand name '''Zenrelia''', is a ] used for the treatment of ] (itching) in dogs.<ref name="CA PDL additions" /><ref name="Zenrelia FOI summary" /> It is a non-selective ].<ref name="Zenrelia FOI summary" />

	Ilunocitinib was approved for medical use in the United States in September 2024,<ref>{{cite web \| title=FDA Approves New Treatment for Allergic Skin Conditions in Dogs \| website=U.S. ] (FDA) \| date=19 September 2024 \| url=https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-new-treatment-allergic-skin-conditions-dogs \| access-date=21 December 2024}} {{PD-notice}}</ref> and in Canada in December 2024.<ref name="CA PDL additions" />		Ilunocitinib was approved for medical use in the United States in September 2024,<ref>{{cite web \| title=FDA Approves New Treatment for Allergic Skin Conditions in Dogs \| website=U.S. ] (FDA) \| date=19 September 2024 \| url=https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-new-treatment-allergic-skin-conditions-dogs \| access-date=21 December 2024}} {{PD-notice}}</ref> and in Canada in December 2024.<ref name="CA PDL additions" />
Line 119:		Line 119:
	]		]
	]		]
			]

			]
			]
			]
			]
			]

	{{Veterinary-med-stub}}		{{Veterinary-med-stub}}

Latest revision as of 06:54, 21 December 2024

Veterinary medication

Pharmaceutical compound

Ilunocitinib
Clinical data

Trade names	Zenrelia
Other names	LY-3411067
License data	US DailyMed: Ilunocitinib
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	CA: ℞-only US: ℞-only
Identifiers
CAS Number	1187594-14-4
PubChem CID	44231134
IUPHAR/BPS	11670
ChemSpider	115006748
UNII	N3TB5AH8B9
ChEMBL	ChEMBL4802241
Chemical and physical data
Formula	C₁₇H₁₇N₇O₂S
Molar mass	383.43 g·mol
3D model (JSmol)	Interactive image
SMILES C1CC1S(=O)(=O)N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4
InChI InChI=InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21) Key:RVOUEXFKIYNODQ-UHFFFAOYSA-N

Ilunocitinib, sold under the brand name Zenrelia, is a veterinary medication used for the treatment of pruritus (itching) in dogs. It is a non-selective janus kinase inhibitor.

Ilunocitinib was approved for medical use in the United States in September 2024, and in Canada in December 2024.

Medical uses

Ilunocitinib is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least twelve months of age.